The FDA wants to end the arrangement that lets a company decide for itself that a food ingredient is safe and never tell the agency, and the penalty for ignoring the new rule is a place in a queue
A company may decide on its own that an ingredient is safe, put it into the food supply, and never mention it to anybody in government.
The Food and Drug Administration filed a proposed rule for public inspection on Monday to end that. It would require any person introducing a substance into interstate commerce under the generally recognised as safe provision of the Federal Food, Drug, and Cosmetic Act to notify the agency of the basis for that conclusion, unless an exception applies. The requirement covers human food and animal food alike, which is why the proposal amends two parts of the regulations rather than one, and it reaches substances that arrive in food indirectly, including from packaging.
Notification is currently voluntary. The document says so in those words.
The enforcement is softer than the headline
What happens to a company that simply does not file is the part worth reading twice.
The rule does not propose to make the substance unlawful, seize it, or bar it from sale. It says that if the notification requirement is not met, the agency would treat that failure as a factor in how it prioritises food substances for post-market review. In other words, the sanction for staying quiet is a better chance of being looked at.
That is a real consequence for a manufacturer, and it is not the same thing as a prohibition.
Twenty-seven years of voluntary filings, counted
The voluntary programme began as an interim pilot created alongside a 1997 proposed rule. The agency's food centre, now the Human Foods Program, filed its first notice in 1998 and had filed over 1,200 by 25 March 2025. The veterinary centre started much later, in 2010, and had filed 75 by 28 March 2025.
Those are the notices the agency received across the whole life of the programme. It has no comparable count of the conclusions companies reached and kept to themselves, which is the gap the proposal is written to close.
Nothing changes soon
The document is a proposal, and its own timetable is long. Comments are due 120 days after publication, and the publication stamp on the filing reads 11 August, which puts the deadline at 9 December. The agency states that late comments will not be considered.
If a final rule follows, it would take effect 60 days after that rule publishes. The mandatory notification sections would then carry a compliance date a further 18 months out. Substances already in interstate commerce get a separate route: a time-limited option, open for one year from the effective date, to make a streamlined submission rather than a full notice.
The cost estimate, and the line inside it
The Office of Information and Regulatory Affairs has determined the proposal is economically significant. Discounted at 7 percent, the agency puts the present value of costs at about $82.3m, in a range from $31.5m to $195.9m, and annualised costs at about $11.7m.
Against a food industry of that size the totals are modest. The distribution is not. The agency states that it estimates the economic impact at more than 3 percent of annual revenue for small entities, and on that basis finds the rule would have a significant economic impact on a substantial number of them.
The rule is signed by Robert F. Kennedy, Jr., as Secretary of Health and Human Services. Its reference list cites an HHS item from March 2025 on directing the FDA to explore rulemaking on the self-affirmation pathway, and a May 2025 document called The MAHA Report.
